TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06252220: First in Human Study in Subjects With Obesity, But Otherwise Healthy

Sponsor: NeuroBo Pharmaceuticals Inc. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 139 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT06252220 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06252220 Rescue Dossier →